Pancreatic cancer is the third-leading cause of cancer death in the United States, and for patients whose tumors spread after initial chemotherapy, the prognosis is brutal: standard second-line regimens typically hold the disease at bay for only about three to four months. A new drug called daraxonrasib just doubled that number.
In a Phase 1/2 clinical trial, patients with advanced, previously treated pancreatic cancer who received daraxonrasib saw a median progression-free survival of 8.5 months, according to results published in the New England Journal of Medicine in spring 2026. The finding was striking enough that the FDA cleared an expanded-access program within 48 hours of receiving the request, a turnaround that typically takes weeks and signals unusual urgency from regulators.
What the trial showed
Daraxonrasib, also known as RMC-6236, is a multi-RAS inhibitor developed by Revolution Medicines, a clinical-stage oncology company based in Redwood City, California. Unlike earlier targeted therapies that block only a single KRAS mutation variant (such as sotorasib and adagrasib, which target KRAS G12C), daraxonrasib is designed to shut down a broader range of RAS-driven signaling. That distinction matters because roughly 90% of pancreatic ductal adenocarcinomas, or PDAC, carry KRAS mutations, making RAS one of the most important molecular targets in the disease.
The drug was tested in the open-label trial RMC-6236-001 (NCT05379985), which enrolled patients with advanced solid tumors harboring specific RAS mutations. The pancreatic cancer cohort included individuals whose metastatic PDAC had already progressed on at least one prior line of therapy and whose tumors carried KRAS G12X alterations. The exact number of patients in the pancreatic cancer cohort is reported in the NEJM’s full text but is not available in public summaries of the trial.
The central result, a median progression-free survival of 8.5 months, stands out against the historical benchmarks set by approved second-line regimens. The NAPOLI-1 trial, which led to FDA approval of nanoliposomal irinotecan plus fluorouracil for this population, reported a median progression-free survival of about 3.1 months. Gemcitabine-based combinations have produced similar figures. The gap between 8.5 months and that range is what has generated excitement among oncologists, though it comes with a critical caveat: these are indirect, cross-trial comparisons, not results from a single randomized study.
Why the FDA moved so fast
On April 28, 2026, Revolution Medicines submitted an expanded-access request to the FDA. Two days later, on April 30, the agency issued a safe-to-proceed letter, allowing the company to offer daraxonrasib to previously treated metastatic PDAC patients outside the clinical trial. The FDA’s announcement described this as an expanded-access program for patients with limited alternatives, not a drug approval.
Expanded access, sometimes called compassionate use, is typically reserved for patients with serious or life-threatening conditions who have no satisfactory treatment options remaining. The FDA must review the drug’s safety profile and confirm that the potential benefits justify the risks. A two-day turnaround on that review is rare and reflects both the severity of advanced PDAC, which kills most patients within a year of diagnosis, and the strength of the early efficacy signal.
What remains uncertain
Several open questions separate these results from a proven treatment advance. The most important: the 8.5-month figure comes from a single-arm cohort with no concurrent control group. Without randomization, the result could partly reflect patient selection. Clinical trials often enroll people who are in better overall health or whose tumors behave differently than the broader patient population. Independent oncology researchers have flagged this limitation, noting that randomized data will be essential before the drug’s true benefit can be measured against a real-world comparator.
The full confidence intervals for the 8.5-month endpoint and detailed patient baseline characteristics appear only in the NEJM’s paywalled full text, which limits independent scrutiny. Without that granularity, it is difficult to know whether most patients clustered near the median or whether a subset of long responders pulled the number upward. It also remains unclear whether the benefit concentrates in patients carrying specific KRAS G12X mutation subtypes or extends across the broader RAS-mutant population. If Phase 3 results show the drug works primarily in a narrower genomic subgroup, regulators could restrict future labeling accordingly.
Safety data from the expanded-access program are also sparse. The FDA’s procedural letter confirmed the program could proceed but did not publish enrollment figures, adverse-event rates, or dosing details beyond what appeared in the Phase 1/2 registry. Early-phase trials of targeted therapies often identify class-related toxicities, but broader use in less carefully selected patients can surface new safety signals. Patients and oncologists considering expanded access will need to weigh the known efficacy signal against an incomplete public safety picture.
There is also the question of sequencing. Many patients with metastatic PDAC now receive combination chemotherapy upfront, and some receive maintenance regimens or targeted agents based on DNA repair defects or other biomarkers. Whether prior drug exposure influences response to daraxonrasib, or whether the agent might eventually be tested earlier in the disease course, remains unknown.
The Phase 3 trial that will settle the debate
Revolution Medicines has already launched a randomized Phase 3 study, RASolute 302 (NCT06625320), comparing daraxonrasib head-to-head against investigator’s choice standard-of-care chemotherapy in the same patient population. The trial’s key endpoints include overall survival and progression-free survival, which should provide the definitive comparison that the single-arm Phase 1/2 data cannot.
The company has stated that the Phase 1/2 results “supported initiation of our randomized Phase 3 program,” tying the earlier findings directly to the decision to pursue a registrational study. If RASolute 302 confirms the benefit seen in the earlier trial, it could lead to full FDA approval and reshape second-line treatment for a cancer that has resisted meaningful progress for decades.
What patients facing second-line treatment should know
For people currently weighing their options after first-line chemotherapy for metastatic PDAC, the most direct path to daraxonrasib is enrollment in an ongoing clinical trial, including RASolute 302. Participation offers access to the drug under careful monitoring and contributes to the evidence base that will determine whether it earns approval. Patients can search for open trial sites through ClinicalTrials.gov or ask their oncologist directly.
If trial enrollment is not feasible, the expanded-access pathway may be available at certain treatment centers. Eligibility and logistics vary, and not every hospital participates. In either case, decisions should account for personal goals, expected quality of life, travel demands, and a clear-eyed understanding that daraxonrasib, despite a genuinely encouraging early signal, has not yet been proven to extend survival in a randomized setting. Pancreatic cancer has taught oncology hard lessons about drugs that looked promising in early trials but failed to deliver in larger studies. This one may be different. The Phase 3 data will tell.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
